ENTRADA THERAPEUTICS INC

Entrada Therapeutics is a clinical-stage biopharmaceutical company whose core business model involves the development of novel therapeutics through preclinical and clinical research. This research and development process inherently requires animal testing to assess the safety and efficacy of drug candidates, as mandated by global regulatory authorities like the U.S. Food and Drug Administration. The company’s lead programs in neuromuscular and ocular diseases are dependent on data generated from animal models to advance toward human trials.

Cruelty Free Investors, an organization that screens for corporate involvement in animal exploitation, categorizes Entrada Therapeutics under “Animal Testing.” The group’s 2024 list of “Companies That Exploit Animals” specifically flags Entrada for this activity, indicating the company’s operations are built on a research pipeline that utilizes animal testing as a standard, non-optional component of the drug development process.